Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What's new in hypochromy.

Thierry Passeron1, Jean-Paul Ortonne

  • 1Department of Dermatology, Hôpital de l'Archet 2, Nice, France. t.passeron@free.fr

The Journal of Dermatological Treatment
|June 13, 2006
PubMed
Summary

Hypochromy, a common skin condition, has limited treatment options. New insights from tyrosine kinase inhibitors offer potential for novel therapeutic strategies to address hypochromic disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Advances in therapy·2026
Same author

The impact of the six pillars of lifestyle medicine on the biology of skin aging.

Frontiers in aging·2026
Same author

Prevalence of melasma, quality-of-life impact and social stigmatization.

Clinical and experimental dermatology·2026
Same author

Combination of Oral Gliadin-Protected Superoxide Dismutase With Targeted Phototherapy in Vitiligo: A Prospective, Comparative, Randomized, Single-Blinded Study.

Photodermatology, photoimmunology & photomedicine·2026
Same author

Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review.

Dermatology and therapy·2026
Same author

Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications.

Dermatology and therapy·2026

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Hypochromy is a prevalent dermatological condition with challenging treatment outcomes.
  • Recent research into tyrosine kinase inhibitors (TKIs) has revealed unexpected pigmentary side effects.
  • These side effects provide novel insights into the pathophysiology of hypochromy.

Purpose of the Study:

  • To explore the understanding of hypochromy pathophysiology.
  • To discuss emerging therapeutic approaches for hypochromy.
  • To highlight the significance of TKI-induced pigmentary changes.

Main Methods:

  • Review of recent dermatological and pharmacological literature.
  • Analysis of reported pigmentary side effects associated with tyrosine kinase inhibition.
  • Discussion of potential therapeutic strategies based on new pathophysiological insights.

Main Results:

  • Tyrosine kinase inhibitors can induce significant pigmentary alterations.
  • These alterations offer a new perspective on melanogenesis and hypochromy.
  • Understanding TKI mechanisms may lead to targeted hypochromy treatments.

Conclusions:

  • The study underscores the potential of TKI-related research for advancing hypochromy treatment.
  • New therapeutic avenues for hypochromy are emerging from TKI research.
  • Further investigation into TKI-induced pigmentation is warranted for clinical application.

Related Experiment Videos